Medtronic, Inc. (MDT) Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study
2/8/2012 6:25:11 AM
MINNEAPOLIS--(BUSINESS WIRE)--Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the one-year results of an international study of the Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA). The device is investigational in the United States.
comments powered by